CONTROL OF SYMPTOMS AND SAFETY WITH THE ADMINISTRATION OF PALIPERIDONE PALMITATE 3-MONTH FORMULATION

Autor/autores: José Ángel Alcalá Partera , Juan Luis Prados Ojeda
Fecha Publicación: 26/07/2017
Área temática: Tratamientos .

Reina Sofia University Hospital. Dept. of Mental Health. Córdoba. Spain.

13th Wold Congress of Biological Psychiatry. 18-22 June 2017. Copenhagen. Denmark.

RESUMEN

The appearance of paliperidone palmitate for quarterly use is an extraordinary advance and novelty from a pharmacokinetic point of view. This treatment may be initiated in patients who are adequately treated with the monthly use formulation for at least 4 months and not require dose adjustment at this time interval.


The objectives of this study are to quantify short- and long-term changes in the symptoms control and patient safety profile.

Palabras clave: PALIPERIDONE, PALMITATE, 3-MONTH FORMULATION,


VOLVER

Url corta de esta página: http://psiqu.com/1-8455